BioSpace News Archive

Aclaris Therapeutics, Inc. announced the completion of enrollment into ATI-450-RA-202, its Phase 2b trial of oral zunsemetinib in patients with moderate to severe rheumatoid arthritis.

Acumen Pharmaceuticals, Inc. announced that it will present topline results from a Phase 1 trial of its candidate ACU193, the first clinical stage AβO-directed antibody therapy, at the Alzheimer’s Association International Conference 2023 taking place in Amsterdam, Netherlands and online from July 16-20, 2023.

First Wave BioPharma, Inc. announced that it has achieved the enrollment target in its ongoing Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation of adrulipase for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.

Ascendis Pharma A/S announced it will showcase its latest Endocrinology Rare Disease programs, data, and research in growth hormone deficiency, hypoparathyroidism, achondroplasia, and Turner Syndrome at ENDO 2023, the annual meeting of the Endocrine Society being held June 15-18 in Chicago.

Charles River Laboratories International, Inc. announced the launch of its off-the-shelf lentiviral vector packaging plasmids, providing a streamlined solution to the challenges associated with plasmid sourcing in cell and gene therapies.

Orthopedic Care Partners, a leading orthopedic practice management platform, announced a strategic affiliation with the American Spine & Orthopaedic Institute, a renowned practice specializing in complex adult and pediatric spine pathology, based in Orlando, FL.